US Pharma MarketingRetraction of high-profile paper on cancer drug timing could hand ammo to China hawks
Nature Medicine retracts China lung cancer immunotherapy timing paper, citing data integrity concerns — and the fallout could fuel US anti-China sentiment in biopharma. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing:…
Nature Medicine has retracted a high-profile paper it published in February detailing the results of a China-based trial suggesting that cancer immunotherapy was more effective if given to lung cancer patients ...
Source: Endpoints News